SHSE:600513 (China)
Ā
Class A
Ā„
9.51
(-1.04%)
Jan 15
Business Description
Jiangsu Lianhuan Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE000001DP6
Share Class Description:
SHSE:600513: Class ACompare
Compare
Traded in other countries / regions
600513.China IPO Date
2003-03-19Description
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include severalĀ series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.25 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.58 | |||||
| Debt-to-EBITDA | 3.94 | |||||
| Interest Coverage | 7.57 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.46 | |||||
| Beneish M-Score | -2.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16 | |||||
| 3-Year EBITDA Growth Rate | 12.5 | |||||
| 3-Year EPS without NRI Growth Rate | 2.8 | |||||
| 3-Year FCF Growth Rate | 21.5 | |||||
| 3-Year Book Growth Rate | 8.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.85 | |||||
| 9-Day RSI | 40.32 | |||||
| 14-Day RSI | 42.83 | |||||
| 6-1 Month Momentum % | 29.02 | |||||
| 12-1 Month Momentum % | 0.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.97 | |||||
| Quick Ratio | 0.71 | |||||
| Cash Ratio | 0.14 | |||||
| Days Inventory | 106.15 | |||||
| Days Sales Outstanding | 78.8 | |||||
| Days Payable | 79.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.56 | |||||
| Dividend Payout Ratio | 0.31 | |||||
| 3-Year Dividend Growth Rate | 21.3 | |||||
| Forward Dividend Yield % | 1.56 | |||||
| 5-Year Yield-on-Cost % | 3.35 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | -2.44 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 50.07 | |||||
| Operating Margin % | 9.12 | |||||
| Net Margin % | 5.95 | |||||
| FCF Margin % | 0.25 | |||||
| ROE % | 10.17 | |||||
| ROA % | 4.81 | |||||
| ROIC % | 7.71 | |||||
| 3-Year ROIIC % | 3.82 | |||||
| ROC (Joel Greenblatt) % | 12.08 | |||||
| ROCE % | 13.07 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.81 | |||||
| PE Ratio without NRI | 19.45 | |||||
| Shiller PE Ratio | 27.97 | |||||
| PEG Ratio | 1.03 | |||||
| PS Ratio | 1.13 | |||||
| PB Ratio | 1.93 | |||||
| Price-to-Tangible-Book | 2.34 | |||||
| Price-to-Free-Cash-Flow | 1535.81 | |||||
| Price-to-Operating-Cash-Flow | 13.73 | |||||
| EV-to-EBIT | 16.95 | |||||
| EV-to-EBITDA | 16.95 | |||||
| EV-to-Revenue | 1.51 | |||||
| EV-to-FCF | 592.25 | |||||
| Price-to-Median-PS-Value | 0.55 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.38 | |||||
| Price-to-Graham-Number | 1.42 | |||||
| Earnings Yield (Greenblatt) % | 5.9 | |||||
| FCF Yield % | 0.21 | |||||
| Forward Rate of Return (Yacktman) % | 11.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
Jiangsu Lianhuan Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil Ā„) | 2,335.273 | ||
| EPS (TTM) (Ā„) | 0.48 | ||
| Beta | 0.97 | ||
| Volatility % | 32.52 | ||
| 14-Day RSI | 42.83 | ||
| 14-Day ATR (Ā„) | 0.610401 | ||
| 20-Day SMA (Ā„) | 10.3095 | ||
| 12-1 Month Momentum % | 0.09 | ||
| 52-Week Range (Ā„) | 6.71 - 13.01 | ||
| Shares Outstanding (Mil) | 285.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jiangsu Lianhuan Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jiangsu Lianhuan Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Ā„) | ||
|---|---|---|---|---|
| No Event Data | ||||
Jiangsu Lianhuan Pharmaceutical Co Ltd Frequently Asked Questions
What is Jiangsu Lianhuan Pharmaceutical Co Ltd(SHSE:600513)'s stock price today?
The current price of SHSE:600513 is Ā„9.51. The 52 week high of SHSE:600513 is Ā„13.01 and 52 week low is Ā„6.71.
When is next earnings date of Jiangsu Lianhuan Pharmaceutical Co Ltd(SHSE:600513)?
The next earnings date of Jiangsu Lianhuan Pharmaceutical Co Ltd(SHSE:600513) is .
Does Jiangsu Lianhuan Pharmaceutical Co Ltd(SHSE:600513) pay dividends? If so, how much?
TheĀ Dividend Yield % Ā of Jiangsu Lianhuan Pharmaceutical Co Ltd(SHSE:600513) is 1.56% (As of Today), HighestĀ Dividend Payout RatioĀ of Jiangsu Lianhuan Pharmaceutical Co Ltd(SHSE:600513) was 0.38. The lowest was 0.21. And the median was 0.27. The Ā Forward Dividend Yield % of Jiangsu Lianhuan Pharmaceutical Co Ltd(SHSE:600513) is 1.56%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers